Thursday, March 17, 2016

Idelalisib - Breaking News

Breaking News: Gilead Sciences Halts Six Idelalisib Combination Trials from Patient Power on Vimeo.

Wednesday, March 2, 2016

Ibrutinib rejected in England

Before the deafening calls for single payer health care overwhelm any thoughtful discussion about how to pay for crazy expensive medications, I thought this article highlights just how much autonomy is removed in such a system.

England Rejects Ibrutinib in CLL

While our system is definitely a broken mess, at least we can prescribe Ibrutinib without having a major fight with insurance in most cases.